/Companies

Carcinotech

Edinburgh, GB · 12 known investors

Find your way into Carcinotech

Sign up to see every warm intro you have to Carcinotech

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Carcinotech team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.

Founders & leadership

L
LornaChief Scientific Officer
A
Albert
I
Ian
S
Susanne

Investors · 12

Also in the syndicate · 1

SIS Ventures

Companies House · registry record

View on Companies House ↗
Registered name
CARCINOTECH LTD
Company number
SC604026
Status
Active
Company type
Private limited company
Incorporated
31 Jul 2018
Registered office
Roslin Innovation Centre, Easter Bush Campus, Edinburgh, Midlothian, EH25 9RG
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement
last made up to 30 Jul 2026 · next due 13 Aug 2027

Current officers · 4

  • Mbm Secretarial Services Limited — corporate secretary, appointed 23 Jan 2023
  • Lorna Ewart — director, appointed 4 Jun 2024
  • Albert Nicholl — director, appointed 2 Oct 2020
  • Ian David Waddell — director, appointed 3 May 2022

Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Carcinotech do?
Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
Who are Carcinotech's investors?
Carcinotech's investors include Alba Equity, TRICAPITAL, British Business Bank, Eos Advisory, Gabriel Investment Syndicate, Investing Women Angels, Investment Fund for Scotland, Maven Capital and 3 more.
Where is Carcinotech headquartered?
Carcinotech is headquartered in Edinburgh, GB.